Business
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023 LOS
About this update from Immix Biopharma, Inc.
[{"type":"text","content":"Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Paris, France 23-26 April 2023\nLOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Paris, France, 23-26 April 2023. “We are delighted to present additional clinical data at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “We are pleased to reach this milestone as we learn more about this promising therapy.” Posters to be presented: Title: “Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center” Event: European Society for Blood and Marrow Transplantation 49th Annual Meeting Dates: April 23-26, 2023 Location: Palais des Congrès de Paris, 2 Pl. de la Prte Maillot, 75017 Paris, France Times: Sunday, April 23 08:30 – 19:20 CEST / Monday, April 24 09:00 – 18:00 CEST / Tuesday, April 25 09:00 – 18:00 CEST / Wednesday, April 26 08:30 – 14:15 CEST Nexcella, Inc. previously announced that NXC-201 (formerly HBI0101) produced a 90% overall response rate (ORR) and 59% complete response/stringent complete response (CR/sCR) at the therapeutic dose from the first 42 patients in an ongoing phase 1b/2a relapsed/refractory multiple myeloma ongoing clinical trial as of the October 23, 2022 data cutoff. NXC-201 also produced 100% hematologic complete response rate and 100% organ response rate (cardiac, liver, renal) in 5 relapsed/refractory AL Amyloidosis patients as of the October 23, 2022 data cutoff. These data were published in Haematologica https://doi.org/10.3324/haematol.2022.281628 (multiple myeloma), Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 (AL amyloidosis), and presented at the European Society for Blood and Marrow Transplantation and European Hematology Associati...